Introduction
Several physiological mechanisms are involved in erectile function. A negative in¯uence of prescription-drugs on these mechanisms will not always come to the attention of the clinician, whereas a drug causing priapism will rarely escape the attention.
When erectile function is in¯uenced in a negative way compensation may occur. For example, agerelated penile sensory disorders may be compensated for by extra stimulation. 1 Diminished in¯ux of blood will lead to a slower onset of the erection, but may be accepted. A mild`venous leak' can be compensated by extra in¯ow of blood 2 and the suboptimal rigidity may be accepted. Therefore a negative in¯uence of medication on the erectile function will not always lead to a complaint.
The problems themselves for which drugs are prescribed, such as cardiovascular disease, psychosis, depression, diabetes mellitus may have a negative effect on sexual and erectile function. In this situation the already compromised system is more vulnerable to adverse effects of medication. Erroneously the erectile dysfunction may be attributed to the disease, instead of the medication. In geriatric patients, who often use several medicines at the same time, the issue is even further complicated. 3 Many patients will not discuss their sexual problems when not invited to do so. In clinical practice all this will result in an underestimation of the drug factor in impotence. It has been estimated that the drug factor plays a role in 25% of patients seeking advice for erectile dysfunction. 4 Patient compliance concerning correct medication usage, is, among other things, dependent on side-effects. In a large follow-up program 8.3% of the male patients stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function. 5 In the drug registration procedures sexual function is not a major issue. This means that knowledge of the problem is mainly dependent on case reports and the lists from side effect registries.
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Another way of looking at the problem is combining available data on mechanisms of action of drugs with the knowledge of the physiological mechanisms involved in erectile function. The advantage of this approach is that remedies may evolve from it.
In this paper we will discuss the subject in the following order: trolled by the well described neural regulation mechanisms. This is however not suf®cient for the development of a rigid erection, since there are shortcuts to the venous channels and the resistance of the lacunar spaces in the corpora cavernosa depends on smooth muscle tone. Relaxation of the smooth muscle cells is necessary for the expansion of the corpora, this is initiated by parasympathetic impulses. Sympathetic tone needs to be reduced, since this causes contraction of the smooth muscle cells. The search for non cholinergic, non adrenergic (NANC) transmission of the impulses of the nervous system to the smooth muscle cells has drawn attention to nitric oxide (NO) as an initiator of a cascade of chemical events that results in relaxation of all the smooth muscle cells of the corpora. 10, 11 After the ®rst impulses, the scarcely innervated network of endothelial cells and smooth muscle cells take care of their own coordination in order to relax all at the same time. This is accomplished through tight junctions and gap junctions. Free in¯ow of blood is allowed in the lacunae, ®nally resulting in such a tumescence that out¯ow of blood will be stopped by compression of the venous channels between the distended corporal tissue and the tunica albuginea. This leads to rigidity of the penis that may be further enhanced by contractions of pelvic¯oor muscles, compressing the crurae of the corpora cavernosa and building a pressure that is higher than the systolic blood pressure. 12 In¯ow of blood to the corpora cavernosa is minimal at that point. The erection comes to an end by renewed contraction of the smooth muscle cells, initiated by sympathetic impulses and by the production of substances such as endotheline-1, prostaglandin F2a and tromboxane A2 by the endothelial cells. 9, 13 This will allow venous out¯ow by decompression of the subtunical venous plexus.
Control mechanisms
Several control mechanisms play a role in sexual behavior and erectile function. Many have effects on the central nervous system as well as on the cardiovascular system. There is an analogy in the responses of blood vessels to these regulation mechanisms and the responses of the tissue in the corpora cavernosa.
Hormonal system
The exact role of testosterone on erectile function is not well de®ned. The negative in¯uence of castration on libido is regularly seen in clinical practice.
The negative effect of castration on erectile function may be secondary to this. Erections during REM sleep are inhibited by castration, suggesting an in¯uence on the central nervous system. 14, 15 The adult corpus cavernosum hardly has any receptors for testosterone, while in children testosterone induces growth of the penis, rather than erections. 16 It has been shown that the hormonal manipulation preceding gender reassignment (pharmacological castration) lowers the amount of nitric oxide synthase (NOS) in the corpus cavernosum tissue. 17 In a rat model nitric oxide mediated erectile activity was a testosterone dependent event, while in another rat model it was shown that dihydrotestosterone levels positively correlate with the amount of NOS in the corpus cavernosum. 18, 19 However, after castration the local mechanisms leading to penile smooth muscle relaxation are not impaired, possibly since compensation occurs by lowering of the sympathetic tone. 20 The testosterone serum level is mainly determined by the epiphyse/pituitary/testes feedback system. Estrogens and steroid-antiandrogens in¯u-ence the testosterone serum level via this system. High prolactin levels also lower the testosterone production. Hyperprolactinaemia may be drug induced. Cimetidine, estrogens, metoclopramide, amethyldopa, morphine and the phenothiazines are known for this. The elevation of prolactin serum levels is usually mild and not accompanied by a decrease in serum testosterone levels. In absence of a low testosterone serum level the relation of hyperprolactinaemia and impotence is unclear and withdrawal of the culprit drug maybe disappointing because of other organic factors determining the erectile dysfunction. 21 Some drugs have an unexpected anti-androgen effect such as H2-antagonists and some antifungal drugs. Effects on the testosterone levels have been described of beta blockers, spironolactone and digoxin, the practical value of these reports is unclear.
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Central nervous system
Emotional and cognitive factors in¯uencing sexual behavior and erectile function are beyond the scope of this review. Several parts of the brain are involved in sexual function and already on this central level integration with autonomous regulation of other body functions is present. The brain may inhibit or facilitate the spinal mechanisms leading to an erection. Among others, the hypothalamic and limbic pathways are intensively studied. The medial preoptic hypothalamic area, in contact with the paraventricular nucleus of the hypothalamus is important for autonomic and neuroendocrine inte-gration. 9 Dopaminergic systems and serotoninergic systems play a major role in sexual behavior and erectile function. 25 For several psychopharmaca these systems are the speci®c target. 26 Apomorphine, a central dopamine agonist, is effective in enhancing sexual behavior in the animal model as well as in humans. 27 For this effect testosterone needs to be present. 28 There is evidence that this effect is also dependent on oxytocine release. 9 Dopamine also has cardiovascular effects, mediated by several distinct types of receptors that vary in their af®nity. In low concentrations dopamine acts on vascular D1 receptors, leading to vasodilatation. In somewhat higher doses it activates the beta-1 adrenoceptors, whereas at high concentrations vasoconstriction is effectuated via activation of vascular alpha-1 adrenoceptors. 29 Of the serotoninergic system mainly the 5-HT 1A , 5-HT 1C and the 5-HT 2 receptor subtypes play a facilitory role in human sexual behavior and antagonists have a negative in¯uence. 25, 26 On this level the explanation may be found why such a marked difference was shown between the effectiveness of several anti-serotoninergic agents in impotence treatment. 30 For a stimulatory effect of 5-HT 1A agonists testosterone needs to be present. 31 Cardiovascular effects of serotonine may be constricting or dilating, depending on the type of receptor activated, while serotonine also in¯uences the release of noradrenaline from adrenergic nerves and stimulates endothelial cells to release prostaglandins and NO. 29 Noradrenergic neurons also play a role in the central regulation of sexual function. 9 Methyldopa, an older antihypertensive drug, may so be responsible for erectile dysfunction. 6 The selective alpha-2 adrenoceptor antagonist yohimbine may improve libido and its main effect in vivo is probably on the central nervous system. 32 Of the central neurotransmitters oxytocin, ACTH and related peptides, prolactin, gamma-aminobutyric acid and endorphins are all implicated in the regulation of sexual behaviour and erectile function. 9 Stress may in¯u-ence the production of endogenous opioids which has re¯ections on the hypothalamic-pituitary-luteinizing hormone axis. 33 
Peripheral nervous system
Somatic pathways are important for sensitivity of the penile skin and the contraction of the pelvic oor muscles. The autonomic nervous system is essential for erectile function. The pharmacology of the autonomic system has been extensively studied. At the ganglionic level (the nicotinic acetylcholine receptor) the system will respond to drugs in the usual way. At this site integration of parasympathetic and sympathetic impulses takes place and the mechanisms of homotropic and heterotropic interaction can be in¯uenced by drugs. The pelvic ganglions are also the site where neuromodulation takes place by various endogenous substances (serotonin, adenosine, histamine, enkephalin and dopamine) at their speci®c receptors. 29 At the peripheral level the existence of different receptor subtypes and the relative af®nity of drugs to these receptors makes prediction of the resulting effect of drugs on the corporal smooth muscle tissue complicated.
Sympathetic nervous system
The smooth muscle has a resting tone that is mainly governed by tonic alpha receptor stimulation. 34 Reduction of sympathetic tone is important to initiate a reaction, but does not result in penile erection. Bilateral sympathectomy does not cause priapism. Psychogenic inhibition of erections is mediated by the sympatic nerves and by circulating catcholamines. 35 Ejaculation is controlled by the sympathetic nervous system. Thereafter detumescence is initiated by the sympathetic pathway, inducing contraction of the smooth muscles of the corpora cavernosa and so allowing out¯ow of blood. Reviewing the subject of receptors, Andersson concludes that for the cavernosal tissue alpha-1 adrenoceptors predominate functionally, alpha-1A and alpha-1C being more numerous than alpha-1B adrenoceptors. 9 Alpha-2 adrenoceptors predominate in the cavernous artery. 9 The beta-2 adrenoceptors, although present, are not supposed to be functionally important. 36 For impotence treatment with drugs applied intracavernously (i.c.) the alpha adrenoceptors are an important target. 37 Blockade of alpha adrenoceptors by medication may cause priapism. 38 
Parasympathetic nervous system
Transection of the nervi erigenti leads to impotence because the induction of smooth muscle relaxation, followed by high in¯ow of blood, is a parasympathic event. 39 The parasympathetic impulse however is not only the result of direct cholinergic transmission by acetylcholine to muscarine receptors on the smooth muscle cells in the corpora cavernosa. It is supposed to have its effect by inhibiting the release of noradrenaline from sympathetic nerve endings and by the release of Non Cholinergic Non Adrenergic (NANC) transmitters from the parasympathetic nerve endings and from the endothelial cells. 9, 40 NO is one of the main NANC transmitters.
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Cavernous tissue function
From his experience with i.c. injection therapy Goldstein 41 formulated a cascade theory, in which he combines pharmacologic events with physiology and anatomy. After an i.c. injection with vaso-active drugs relaxation on that site in the cavernous tissue leads to local increase of blood in¯ow. This if followed by activation of endothelium-mediated relaxation factors, the zone of muscle relaxation is enlarged, leading to local increase of blood in¯ow etc. If any part of the corpora cavernosa is not completely relaxed, venous return is not suf®ciently stopped and rigidity is suboptimal or of short duration. This is the equivalent of the clinical concept of`venous leakage' that may be quanti®ed by cavernosometry. 42 The pathways by which the smooth muscle cells communicate and the role of the endothelial cells of the corpora cavernosa are under investigation.
The smooth muscle cells are in contact with each other through gap junctions. In cavernous tissue they consist mainly of calcium and potassium channels. 43, 44, 51 In this way integrated action is possible, since this allows for relatively unimpeded intercellular transit of current carrying ions and transit of small metabolites and second messengers as inositol triphosphate, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphatase (cGMP). For more details we refer to excellent reviews on this matter from Andersson and Christ. 9, 45 Several products of the nerve endings and the endothelial cells can initiate smooth muscle relaxation, such as NO, vasoactive intestinal peptide (VIP), neuropeptide Y, calcitonin gene related peptide, substance P, prostanoids. 46, 47 Especially NO has drawn much attention as an important regulator of smooth muscle tone in the corpora cavernosa. 10, 11 NO is produced by autonomic nerve endings and by endothelial cells from L-arginine and molecular O 2 by NO synthase (NOS). NOS is available in several isoforms and its production can be stimulated in several ways. 48 In chronic hypoxic states NO formation is reduced. 49 NO activates guanylate cyclase, the conversion of GTP to cGMP lowers the calcium concentration and leads to relaxation of the smooth muscle. In addition to the cGMP pathway, activation of NA/Ka-ATPase may also play a role in the relaxation of corpus cavernosum tissue by NO. 50 Cyclic nucleotide phosphodiesterases (PDE) are enzymes that hydrolyse cGMP and cAMP to monophosphates. PDE may be blocked by pharmaca, for example papaverine. 51, 52 Several PDE subtypes can be identi®ed. In the corpora cavernosa PDE 5 is predominant and this subtype is blocked by sildena®l. 53, 54 These insights in the physiology of the corpus cavernosum have already led to new possibilities for i.c. injection therapy, for example the use of the NO donors linsidomin and of calcitonin gene related peptide. 55, 56 The data from research of oral medication acting on these systems becomes available now. 53, 54, 57 Prescription drugs
Psychotropic drugs
Especially antipsychotic and antidepressant drugs are known for their side effects on erectile function. 6±8 In clinical practice the patients in need of these drugs may not be ideal candidates to have their sexual performance evaluated. Much is known from animal studies. Side effects may be due to adrenergic, anticholinergic, dopaminergic or serotoninergic effects. 58 Other psychotropic drugs such as benzodiazepines, are reported to cause impotence. Maybe this effect is simply the result of sedation. 6 Unexplained is the ®nding that lithium when combined with benzodiazepines is associated with sexual dysfunction in almost half of the patients. 59 Antipsychotics and antidepressants have an effect on the dopaminergic and the serotinergic central nervous system that may be stimulating or inhibiting. The combination of stimulating central effects with periferal alpha-blocking properties may induce priapism, because the alpha receptors in the cavernous tissue are important for contraction of smooth muscle cells and so the initiation of detumescence. The most reported antidepressant drug that causes priapism is trazodone. 60 This antidepressant drug has been applied i.c. and induced smooth muscle relaxation. 61 It is also known for its ability to improve libido. 62, 63 Clomipramine, a tricyclic antidepressant that combines serotonin reuptake inhibitor properties with alpha blocking properties is more effective for treatment of premature ejaculation, than for treatment of erectile dysfunction. 64 Fluoxetine has been associated with erectile dysfunction as well as with the return of potency. 8, 65 More consistent is its postponing effect on the ejaculation. 66 When erectile dysfunction is caused by a tricyclic antidepressant drug it may be rational to try the patient on trazodon or¯uoxetine instead. 67 However one must consider the possibility that erectile dysfunction might persist in the presence of an increased libido.
Of several antipsychotics the alpha-blocking properties are known, so in case of drug induced impotence one might consider an alternative drug with stronger alpha-blocking properties, a higher af®nity for the alpha-1 receptor. The af®nity for the alpha-1 receptor in decreasing order is: thioridazine, 68 When the alphablocking properties induce priapism, an alternative antipsychotic must be used with a lower af®nity to the receptor. The susceptibility of the patient may change with time and also co-medication with alpha-blocking properties must be considered. Recurrent priapism due to depot zuclopentixol has been reported. 69 
Cardiovascular drugs
To initiate an erection a generous in¯ow of blood is needed. The classical combination of claudicatio intermittents and impotence, due to stenosis of central arteries is known as the Leriche syndrome. Arteriosclerosis is accompanied by degenerative changes in the corpus cavernosum. 70, 71 These changes make the veno-occlusive mechanism less effective. Dysfunction of the corpus cavernosum tissue is the main cause of`venous leakage'. 42 The combination of in¯ow reduction with a diminished possibility to trap the blood in the penis, is detrimental for erectile function. 2 The patient in need of cardiovascular drugs already has a vulnerable erectile function and they will be more susceptible for medication induced erectile dysfunction. In addition to this, many cardiovascular drugs have a direct in¯uence on the autonomous innervation of the penis. Betablocking agents are known for their negative effects on erectile function. This may be due to their effect on the beta adrenoceptors in the corpora cavernosa, but these are underrepresented in the cavernous tissue (alpha receptors outnumber beta adrenoceptors 10±1). 36 Another explanation is a change in balance between alpha and beta sympathetic in¯uence, resulting in insuf®cient antagonism of the alpha-1 vasoconstriction. 72 When betablocking agents prescribed for high bloodpressure cause impotence, an alpha-blocking agent may be a good alternative. Even alphablocking agents have been implicated as the cause of erectile dysfunction. 7, 8 This may be due to the lowering of the bloodpressure as such. 73 Possibly making these patients more vulnerable for a steal phenomenon. Alphablocking agents have an effect on the ejaculation, they may delay ejaculation or cause a retrograde ejaculation and so give rise to secondary (psychogenic) erectile dysfunction. Alphablockers interfere with the sympathetic induced detumescence and may cause priapism.
Several vasodilators have a relaxing effect on the corporal tissue when applied intracavernously or even topically, but this effect is not obvious when these drugs are taken orally. Many vasodilators act upon the calcium and potassium channels. Calcium reentry blocking agents are considered safe treatment as far as erectile function is concerned. 74 On cavernous smooth muscle they have a relaxing effect. 75 When injected i.c. they induce erections. 76 However they are reported as responsible for erectile dysfunction. 7, 8 This may be due to the drop in blood pressure, provoking a sympathetic nervous system response. 76 Potassium channel openers, with pinacidil as well studied example, do show an erectogenic effect when directly applied to the corporal tissue. But taken orally potassium channel openers are not suitable for impotence treatment because of insuf®cient tissue selectivity and the stimulation of the sympathetic nervous system. 77±79 Minoxidil is an exception in this respect, being applied as ointment for induction of tumescence, while taken orally it has been reported to cause priapism. 80 The above mentioned mechanisms may play a role in impotence caused by ACE-antagonists. Since angiotensin converting enzyme (ACE) inhibitors may be responsible for gynecomastia, a hormonal in¯uence also seems possible. 81 The older cardiovascular drugs have important effects on the central nervous system, for example methyldopa in¯uen-cing central alpha-2 activity. 6 Erectile disorders caused by diuretics have been reported, the mechanism is unknown. Digoxin-associated impotence has recently been studied extensively and the underlying mechanism was shown to be inhibition of the Na/Ka-ATPase pump. 82 The authors even remarked that digoxin might prove useful to inhibit erectile activity, for example after penile surgery.
In only a few comparative studies of different bloodpressure lowering regimes sexual function has been evaluated. In a trial with 626 men in need of antihypertensive treatment, 44% had a complaint on sexual functioning at the start of the trial. Half of these complaints concerned erectile function. The group on the ACE inhibitor captopril had as many patients improving as deteriorating (18%), while the patients on the beta adrenoceptor blocker propranolol and the patients on methyldopa improved in 9% and worsened in 25%. Of the patients who needed additional diuretics later in the trial, the patients on propranolol and a diuretic had extra problems with erectile function. 83 A comparison between a diuretic (hydrochlorothiazide) and an alpha adrenoceptor blocker (prazosin) showed that nocturnal erections were more rigid after the use of the alpha adrenoceptor blocker. 84 In a comparison of chlothalidone, acebutolol, doxazosin, amlodipine, enapril and placebo for hypertension treatment, pre-existing problems with erectile function improved with all patients on doxazosin (an alpha blocking agent). 85 Often cardiovascular drugs have a negative effect on erectile function, but disease related problems and drug related problems are hard to distinguish in the clinical setting. Any cardiovascular drug may cause erectile dysfunction. ACE inhibitors, calcium channel blockers and alpha blockers should be considThe in¯uence of medication on erectile function W Meinhardt et al ered as alternatives in case of drug induced impotence. 74 
Miscellaneous drugs
Histamine H 2 -antagonists (used to lower gastric acid secretion) are related to impotence. H 1 , H 2 and H 3 receptors have been found in the corpus cavernosum and stimulation leads to contraction of the smooth muscle cells. 86 H 2 receptors are not considered functionally important in the corpora and H 2 -antagonists applied i.c. have no effect on erectile function. 86 Therefore the explanation of erectile dysfunction due to H 2 -antagonists is probably their anti-androgenic effect. 87 Since these drugs are in the top-ten of prescription drugs the problem is relevant in spite of the probably low frequency in which it becomes manifest. Cimetidine was the ®rst drug from this class associated with impotence, but there is no reason to assume the other H2-antagonists are free of this problem. 8, 88 When it occurs, the medication must be changed to a completely different class of drugs, for example antacids.
Analgesics of the nonsteroid anti-in¯ammatory type (NSAID) are consistently reported as responsible for erectile dysfunction. 7, 8 Several prostanoids are synthesized in the corpus cavernosum and they have various effects on the smooth muscle. 89 This may explain the negative effects of some NSAIDs. In practice the problem is not frequently seen, taking into account that these drugs are taken very often.
Anti-androgens, prescribed for prostate cancer, will commonly lead to impotence. This effect is related to lowering testosterone to castration level which is caused by LHRH-agonists and by steroidal antiandrogens. When the patient cannot accept this side effect, it is possible to treat them with nonsteroidal antiandrogens, or treat them intermittently. 90±92 Whether these approaches are oncologically safe, has still to be established. Finasteride, a drug that blocks the conversion of testosterone into dihydrotestosterone and is used for symptomatic benign prostate hyperplasia, has caused impotence in 3.7% of the cases. 93 Recently some doubt is cast on the notion that dihydrotestosterone is not necessary for erectile function. 19 Drugs to treat impotence Extensive reviews, for oral medication and for drugs for i.c. use, were published in this journal. 32, 94 The alpha-2 adrenoceptor yohimbine has been used for its libido enhancing and its erection improving properties. The main pharmacological property is alpha-blockade. In a double blind study good responses were noted in 21 and 13.8% for 6 mg yohimbine three times daily and placebo. 95 This type of study is necessary before any claim can be made for this indication. Alpha-2 adrenoceptor blockade as such is insuf®cient for impotence treatment. Recently a study with more than 300 patients using placebo or delequamine orally was stopped because no bene®ts could be proven. 96 Alpha 2 -blockade may be rational only in the younger age group with`pure' psychogenic impotence. 97 The combination of central effects on the serotinine system combined with periferal alpha adrenoceptor blocking properties as is seen in trazodone, has been advocated for oral impotence treatment. 98 In a double blind placebo controlled trial we were unable to detect any bene®cial effect beyond the placebo effect. 99 Combining drugs may give synergistic effects. The combination of 50 mg trazodon with 15 mg yohimbine has recently been reported useful in a group of patients without physical abnormalities detectable. The responders had suffered impotence for a signi®cant shorter period before treatment was started (6 vs 18 months). 100 Apomorphine, a dopamine agonist, can induce erections in patients who have no organic problems, but it has many side effects. 101 The opiate antagonist naltrexone has been tried on idiopathic impotence patients, with positive effects only on the selfreported early-morning erections. 102 Presently trials are conducted with drugs that have their rationale in the new insight in corpus cavernosum physiology. The nitric oxide precursor 1-arginine has been tested, however the preliminary favorable data need con®rmation. 57 A trial with oral medication that inhibits type V cGMP-speci®c phosphodiesterase, UK-92,480 (sildena®l), showed favourable results in impotence patients with no known organic cause. 53, 54 Guidelines for clinical practice It would be ideal to obtain information on the sexual function of any patient before medication is prescribed. Once the patient has been asked about it, he knows his doctor is interested and the issue can be discussed in the future. When the patient complains about impotence after exposure to a drug, ®rst of all the exact nature of the complaint must be established. Ejaculation disorders must be differentiated from erectile failure. (Ejaculation disorders are also frequently drug related.) The time relationship between the start of the medication and the start of the complaint must be established. When the drug is known to be related to erectile disorders, see Table  1 , an alternative drug may be tried. Suggestions are given in the earlier sections. When the drug is not known to cause impotence, detailed follow-up after dicyclomine  diethylpropion  diphenydramine  digoxin  dihydralazine  dihydroergotamine  dimenhydrinate  disopyramide  disul®ram  dixyrazine  dosulepin  doxepin  doxylamine  droperidol  ephedrine  enalapril  ergotamine  estrogens  ethionamide  eto®brate  famotidine  felodipine  fen¯uramine  feno®brate  ®nasteridē  ecainidē  uanisonē  uphenazinc  unarizinē  unitrazepam  uocortolonē  uoxetinē  upentixol  urazepam  uspirilenē  utamidē  uvoxamine  gem®brozil  gestagenen  gestonoron caproate  glutethimide  glycopyrrolat  glycopyrronium bromide  goserelin  guanabenz  guanadrel   guanethidine  guanfacine  guanidine  guanoclor  guanoxan  haloperidol  hexamethonium  homatropine  hydantoins  hydralazine  hydrochlorothiazide  hydrocortisone  hydromorphone  hydroxycholorquine  hydroxyprogesterone  hydroxyzine  hyoscyamine  imipramine  indapamide  indometacin  interferon  iodide  iproniazid  isocarboxazid  isoniazid  isopropamide  itraconazole  ketamine  ketanserin  ketazolam  ketoconazole  labetalol  leuproreln  levomepromazine  lisinopril  lithum  lofepramine  lorazepam  lormetazepam  loxapine  maprotiline  mazindol  mebanazine  mecamylamine  medroxyprogesterone  melperon  mepenzolate  mepindolol  meprobamate  mesoridazine  mesterolone  metaclazepam  methadilazin  methadone  methamphetamine  methanteline  methaqualone  methazolamide  methotrexate  methyldopa  methylphenobarbital  methylprednisolone  methyltestosterone  methysergide  metipranolol  metixene  metoclopramide  metoprolol   metronidazole  metyrosine  mexiletine  midazolam  minoxidil  moclobemide  morphine  nadolol  naltrexone  naproxen  nifedipine  nitrazepam  nitrendipine  nizatidine  nordazepam  norethandrolone  norethindrone  norlutin  nortriptyline  omeprazole  opipramol  orphenadrine  oxazepam  oxazolam  oxprenolol  oxybutynin  oxycodone  oxymetazoline  oxypertine  oxyphencyclimine  oxyphenonium  paramethasone  pargyline  paroxetine  penbutolol  pentazocine  pentobarbital  perazine  perhexiline  pericyazine  perphenazine  pethidine  phencyclidine  phendimetrazine  phenelizine  phenmetrazine  phenobarbital  phenoxybenzamine  phenylephrine  phenytoI È ne  phentermine  phenylpropanolamine  pimozide  pindolol  pipamperone  pipoxolan  pirenzepine  piritramide  pizotifen  poldine  polythiazide  pramiverine  prazepam  prazosin  prednisolone  prednisone  prednylidene  pridinol (continued)
The in¯uence of medication on erectile function W Meinhardt et al dechallenge is recommended. When erectile function is restored in a reasonable period of time, then a rechallenge should be considered and the case may be reported. Priapism is easy to diagnose. The problem must be treated within 8 h. 103 Delay may impair future erectile function of the patient and may have legal sequelae. In these cases the alpha adrenoceptor blocking properties of future medication must be considered, especially with psychotropic pharmaca, cardiovascular drugs and medication for urinary out¯ow obstruction. 
